Tumor metabolic reprogramming has been recognized as a critical determinant in tumor development and cancer immunotherapy response. Aberrant choline metabolism is emerging as a defining hallmark of cancer. In this study, we found that carbohydrate-responsive element-binding protein (ChREBP)–mediated choline deprivation induced tumor-associated macrophage (TAM) reprogramming and maintained an immunosuppressive tumor microenvironment. Mechanistically, ChREBP interacted with SP1 to increase the expression of immunosuppressive chemokines CCL2 and CCL7 and choline transporter SLC44A1. As such, high CCL2 and CCL7 expression promoted recruitment of TAMs. Tumor cells with high SLC44A1 levels competed with M1-like TAMs for choline, inhibiting cGAS/STING signaling and promoting the repolarization of M1-like to M2-like macrophages. Clinically, ChREBP–SP1–choline metabolism axis expression was associated with poor clinical outcome in colorectal cancer. Thus, the study identified the interplay between tumors and TAMs via choline competition as a previously unknown immune evasion mechanism in the tumor microenvironment and proposes ChREBP as a potential immunotherapeutic target in cancer. Significance: ChREBP induces a choline-deprived tumor microenvironment and promotes chemokine secretion to facilitate immune evasion, suggesting targeting ChREBP as a therapeutic approach to improve the efficacy of immunotherapy.
20 November 2025 in Journal of Experimental & Clinical Cancer Research
Therapeutic resistance and recurrent metastasis continue to pose major obstacles in the treatment of malignant tumors worldwide. Immunogenic cell death (ICD), characterized by its ability to both eliminate cancer cells and stimulate antitumor immune responses, has emerged as a promising strategy in the field of cancer immunotherapy. As key subtypes of ICD, pyroptosis and necroptosis contribute significantly to remodeling the tumor microenvironment (TME) and modulating immune responses through their distinct death-immunity coupling mechanisms. Characterized by plasma membrane pore formation and subsequent release of cytoplasmic contents, pyroptosis and necroptosis reprogram the immune microenvironment, thereby laying the groundwork for enhanced antitumor immune responses. Paradoxically, the chronic activation of pyroptosis and necroptosis pathways may contribute to cancer progression. Sustained inflammation within the TME promotes the release of pro-angiogenic and immunosuppressive factors, driving myeloid-derived suppressor cells (MDSCs) recruitment, extracellular matrix remodeling, and metastatic niche formation, thereby facilitating tumorigenesis and metastasis. The context-dependent dual roles of pyroptosis and necroptosis—shaped by tumor histotype, chronic inflammation, and stromal context—highlight the need for a nuanced understanding of their tumor-specific functions across cancer types. This review outlines the underlying mechanisms of pyroptosis and necroptosis, and summarizes recent advances, aiming to inform and inspire novel strategies in overcoming cancer immunotherapy resistance.